Critical care explorations - Crit Care Explor
Publications
- 2021
Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock - A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study)
Bauer, M., Weyland, A., Marx, G., Bloos, F., Weber, S., Weiler, N., Kluge, S., Diers, A., Simon, T. P., Lautenschläger, I., Gründling, M., Jaschinski, U., Simon, P., Nierhaus, A., Moerer, O., Reill, L., Jörres, A., Guo, R., Loeffler, M., Reinhart, K. & Riedemann, N., 11.2021, In: Critical care explorations. 3, 11, e0577.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review